<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106962</url>
  </required_header>
  <id_info>
    <org_study_id>001-Boiskin</org_study_id>
    <nct_id>NCT02106962</nct_id>
  </id_info>
  <brief_title>Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients</brief_title>
  <official_title>The Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Institute of Renal Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imprimis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>California Institute of Renal Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how the use of Tranexamic acid and Bacitracin applied to the
      bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and
      Infection Rate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visit 1 - Initial Application:

        -  A patient candidate identified by the PI who meets all of the inclusion criteria and
           none of the exclusion criteria will be consented for the study.

        -  The medical history will be collected from the subject.

        -  The subject will receive routine hemodialysis

        -  Directly after the completion of hemodialysis, the following study drug application
           steps will occur:

             1. Site 1 Initial Compression: Apply fixed amount of Tranexamic acid and bacitracin 5%
                or 25% to gauze and compress for 3 minutes to needle site 1.

             2. Site 2 Initial Compression: Apply fixed amount of Tranexamic acid and bacitracin 5%
                or 25% to gauze and compress for 3 minutes to needle site 2.

             3. Second Compression per site: If bleeding has not stopped, repeat application with
                new gauze and same amount of ointment to each respective site and compress for 5
                minutes more at each site.

             4. Third Compression per site: If after the second application and compression the
                bleeding persists repeat both application and compression for another 5 minutes
                (total time would be 13 minutes at this step).

             5. Test Failure: If after the third application to each needle site there is still
                bleeding, the testing would be considered a failure and routine procedures should
                be utilized to stop the bleeding.

        -  Any adverse events will be collected.

      Visit 2 - Follow-Up:

      â€¢ The 1 week follow up visit will be performed to review study drug application site and to
      collect any adverse events reported by subject

      The clotting time will be compared to the clotting time at a different dialysis session in
      which no treatment will be used
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clotting TIme</measure>
    <time_frame>13 minutes</time_frame>
    <description>After completing dialysis, the clotting time of the arteriovenous fistula of each participant was measured, using either Tranexamic Acid 5% or Tranexamic Acid 25% and compared to the regular clotting time of the AV Fistula without using the Tranexamic Acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Infection</measure>
    <time_frame>2 months</time_frame>
    <description>After using Tranexamic Acid and Bacitracin, local infection rate measured at the end of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Clotting time Using Tranexamic Acid 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clotting Time Using Tranexamic Acid 25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Tranexamic Acid 5% with bacitracin</intervention_name>
    <description>Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.</description>
    <arm_group_label>Clotting time Using Tranexamic Acid 5%</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Tranexamic Acid 25% with bacitracin</intervention_name>
    <description>Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.</description>
    <arm_group_label>Clotting Time Using Tranexamic Acid 25%</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dialysis patients with fistulas (native arterio-venous)

        Exclusion Criteria:

          -  Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.

          -  Active infection.

          -  Stenosis of fistula.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Boiskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Institute of Renal Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fresenius Medical Care - Kearny Mesa</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Insitute of Renal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenious Medical Care - Rancho</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <results_first_submitted>July 28, 2016</results_first_submitted>
  <results_first_submitted_qc>August 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2017</results_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>California Institute of Renal Research</investigator_affiliation>
    <investigator_full_name>Mark Boiskin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>fistula</keyword>
  <keyword>clotting</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>bacitracin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topical Tranexamic Acid 5%</title>
          <description>Topical Tranexamic Acid 5% with bacitracin applied to the arterio-venous fistula site after completing dialysis, to measure clotting time.</description>
        </group>
        <group group_id="P2">
          <title>Topical Tranexamic Acid 25%</title>
          <description>Topical Tranexamic Acid 25% with bacitracin applied to the arterio-venous fistula site after completing dialysis, to measure clotting time.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>dialysis subjects using arteriovenous fistula for dialysis access</population>
      <group_list>
        <group group_id="B1">
          <title>Topical Tranexamic Acid and Bacitracin 5%</title>
          <description>Topical Tranexamic Acid 5% with bacitracin applied to the arterio-venous fistula site after completing dialysis, to measure clotting time in the same participants that did not receive treatment at a subsequent dialysis session</description>
        </group>
        <group group_id="B2">
          <title>Tranexamic Acid and Bacitracin 25%</title>
          <description>Topical Tranexamic Acid 25% with bacitracin applied to the arterio-venous fistula site after completing dialysis, to measure clotting time in the same participants that received treatment but at a subsequent dialysis session.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clotting TIme</title>
        <description>After completing dialysis, the clotting time of the arteriovenous fistula of each participant was measured, using either Tranexamic Acid 5% or Tranexamic Acid 25% and compared to the regular clotting time of the AV Fistula without using the Tranexamic Acid</description>
        <time_frame>13 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clotting Time Using Tranexamic Acid 5%</title>
            <description>Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
Topical Tranexamic Acid 5% with bacitracin: Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.</description>
          </group>
          <group group_id="O2">
            <title>Clotting Time Using Tranexamic Acid 25%</title>
            <description>Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
Topical Tranexamic Acid 25% with bacitracin: Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.</description>
          </group>
        </group_list>
        <measure>
          <title>Clotting TIme</title>
          <description>After completing dialysis, the clotting time of the arteriovenous fistula of each participant was measured, using either Tranexamic Acid 5% or Tranexamic Acid 25% and compared to the regular clotting time of the AV Fistula without using the Tranexamic Acid</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Infection</title>
        <description>After using Tranexamic Acid and Bacitracin, local infection rate measured at the end of study</description>
        <time_frame>2 months</time_frame>
        <population>no local infection in any particioant</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Tranexamic Acid 5%</title>
            <description>Measure clotting time of Native arteriovenous fistula after applying topical Tranexamic Acid 5% compared with normal clotting time</description>
          </group>
          <group group_id="O2">
            <title>Topical Tranexamic Acid 25 %</title>
            <description>Measure clotting time of Native arteriovenous fistula using Tranexamic acid 25% compared with normal clotting time</description>
          </group>
        </group_list>
        <measure>
          <title>Local Infection</title>
          <description>After using Tranexamic Acid and Bacitracin, local infection rate measured at the end of study</description>
          <population>no local infection in any particioant</population>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Topical Tranexamic Acid 5% and Bacitracin</title>
          <description>Topical Tranexamic Acid 5% with bacitracin applied to the arterio-venous fistula site after completing dialysis, to measure clotting time.</description>
        </group>
        <group group_id="E2">
          <title>Topical Tranexamic Acid 25% and Bacitracin</title>
          <description>Topical Tranexamic Acid 25% with bacitracin was applied to the arterio-venous fistula site after completing dialysis, to measure clotting time at a subsequent dialysis session.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark M. Boiskin, M.D.</name_or_title>
      <organization>California Insitute of Renal Research, Inc.</organization>
      <phone>858-637-4600</phone>
      <email>mboiskin@bnmg.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

